Lynda C Schneider
Overview
Explore the profile of Lynda C Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
3065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pongracic J, Gagnon R, Sussman G, Siri D, Oriel R, Brown-Whitehorn T, et al.
J Allergy Clin Immunol Pract
. 2025 Mar;
PMID: 40023371
Background: Due to limited treatment options for peanut allergy, patients remain at risk for allergic reactions due to accidental exposure. Epicutaneous immunotherapy (EPIT) is a novel treatment being investigated for...
2.
Boguniewicz M, Levy M, Eichenfield L, Lauren C, Leung D, Schneider L, et al.
J Pediatr Clin Pract
. 2025 Feb;
14:200121.
PMID: 39950052
Objective: This expert-led consensus aims to provide primary care providers (PCPs) with recommendations for the care of atopic dermatitis (AD) in patients aged <18 years. The first point of contact...
3.
Eichenfield L, Boguniewicz M, Lauren C, Leung D, Levy M, Schneider L, et al.
Dermatology
. 2024 Oct;
240(5-6):897-909.
PMID: 39406204
Atopic dermatitis (AD) is a chronic, type-2 mediated, inflammatory skin disease characterized by intense pruritus, disruption of skin barrier function, and immune dysregulation. Management strategies for AD are routinely determined...
4.
Paller A, Silverberg J, Gonzalez M, Schneider L, Sidbury R, Chen Z, et al.
Front Pediatr
. 2024 Sep;
12:1446779.
PMID: 39318611
Background: Moderate-to-severe atopic dermatitis (AD) often has a profound impact on the quality of life of young children and their caregivers. One of the most burdensome symptoms reported by patients...
5.
Benedetto A, Boguniewicz M, Ong P, Chu D, Schneider L
J Allergy Clin Immunol Pract
. 2024 Sep;
12(11):2955-2965.
PMID: 39251015
Atopic dermatitis is a common chronic inflammatory skin disorder, with a complex pathogenesis. It is characterized by eczematous skin lesions, pruritus, and recurrent skin infections and has a negative impact...
6.
Treffeisen E, Cromer S, Dy-Hollins M, Lin S, Naik H, Graham D, et al.
Acad Pediatr
. 2024 Aug;
25(1):102565.
PMID: 39181503
Objective: To assess whether child food allergy is associated with family food insecurity, overall, and across different income levels. Methods: We used the 2011-2018 National Health Interview Survey, a nationally...
7.
Tsai S, Gaffin J, Hawryluk E, Ruran H, Bartnikas L, Oyoshi M, et al.
Allergy
. 2024 Aug;
79(10):2748-2758.
PMID: 39166365
Background: Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed...
8.
Treffeisen E, Mepyans C, Conroy E, Baer H, Williams D, Williams K, et al.
J Allergy Clin Immunol Pract
. 2024 Aug;
12(11):3081-3088.e6.
PMID: 39117271
Background: Sunflower seeds are a popular allergen-free peanut alternative. Objective: To describe sunflower seed allergy incidence and characteristics. Methods: We conducted a retrospective cohort study of patients with sunflower seed...
9.
Tsai S, Phipatanakul W, Hawryluk E, Oyoshi M, Schneider L, Ma K
J Allergy Clin Immunol
. 2024 Aug;
154(5):1195-1203.e3.
PMID: 39097196
Background: Systemic Janus kinase inhibitors (JAKi) and dupilumab both have emerged as promising therapeutics for atopic dermatitis (AD). Dupilumab has a favorable safety profile, but oral JAKi therapy has been...
10.
Banzon T, Leung D, Schneider L
J Food Allergy
. 2024 Jul;
2(1):35-38.
PMID: 39022136
Atopic dermatitis (AD), characterized by intense pruritus, eczematous lesions, and a relapsing disease course, is a chronic inflammatory skin disease that affects both children and adults. AD often begins in...